About Excellgene
Excellgene is a Healthcare company based in Monthey (Switzerland) founded in 2001, and was acquired by ARCHIMED in October 2025. Services from DNA vectors to purified protein production are provided. Excellgene offers products and services including CHO Cell Line Development, HEK Cell Line Development, and cGMP Cell Bank Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Mammalian Cell Line. Its legal entity is ExcellGene SA.
Company details
ExcellGenes service offer covers the value chain from a DNA vector to a purified protein made by CHO or any other animal cells in bioreactors, ranging from milliliters to the multi-hundred-liter scale of operation. It offers services for protein production; generation and optimization of stable mammalian cell-lines; Process Development and Scale-Up; protein recovery and analysis; and Consulting services. The companys technologies of transient and stable gene expression and scalable disposable cultivation systems support its clients from early discovery, pre-clinical testing through to clinical testing and to manufacturing.
- Headquarters Monthey, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website excellgene.com
- Social LinkedIn Facebook
- Acquired by ARCHIMED (Oct 2025)
- Legal Name Excellgene Sa
Products & Services of Excellgene
Excellgene offers a comprehensive portfolio of products and services, including CHO Cell Line Development, HEK Cell Line Development, and cGMP Cell Bank Manufacturing.
Delivers high-yielding stable CHO clones for biologics production.
Provides superior HEK 293 clones for challenging protein expression.
Prepares compliant cell banks for scalable biopharmaceutical processes.
Investors in Excellgene
Excellgene has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ARCHIMED.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare industries are funded and supported globally by ARCHIMED. | archimed.group | Lyon, France |
Investor details for Excellgene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Excellgene
14 people are tracked at Excellgene (8 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Joeri Kint | Vice President Of Global Business Development & Sales | Leadership |
Maria João Wurm | CEO | Leadership |
Barbara Giorgio | Supply Chain, Procurement & Maintenance Director | Leadership |
Divor Kiseljak | Chief Operating Officer | Leadership |
Paco Pino | Director R&d | Leadership |
Lucien Delapraz | Head Of HR | Leadership |
Benjamin Moritz | Senior Director Of Business Development & Technical Partnership | Leadership |
Concetta Cardone | Head Of Marketing & Design | Leadership |
Katerina Rostova | Business Development Manager, Europe | Team |
Brooke Williams | Business Development Manager | Team |
Romain Hüe | Cell Line Development Associate | Team |
Louise Bryan | Group Leader | Team |
Jean Troyon | Program Officer | Team |
Frédéric Kohler | Cell Culture Associate | Team |
Complete people profiles for Excellgene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Excellgene
2 dated milestones of Excellgene across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Excellgene is founded.
- Exit Acquired by ARCHIMED.
Web traffic of Excellgene
The website of Excellgene (excellgene.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 1990.2% vs previous month
Websites whose visitors overlap most with Excellgene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dna20.com | dna20.com | 100% | – | ||
| geneart.com | 89% | View details | |||
| celprogen.com | 89% | #3,394,353 | View details | ||
| cellcentric.com | 89% | 5.5K | #3,262,513 | View details | |
| genaxxon.com | 89% | 16.5K | #1,573,860 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Excellgene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Excellgene
Complete news archive for Excellgene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Excellgene
Excellgene was founded in 2001.
Excellgene is headquartered in Monthey, Switzerland. It is registered at Monthey, Valais, Switzerland.
ExcellGenes service offer covers the value chain from a DNA vector to a purified protein made by CHO or any other animal cells in bioreactors, ranging from milliliters to the multi-hundred-liter scale of operation. It offers services for protein production; generation and optimization of stable mammalian cell-lines; Process Development and Scale-Up; protein recovery and analysis; and Consulting services. The companys technologies of transient and stable gene expression and scalable disposable cultivation systems support its clients from early discovery, pre-clinical testing through to clinical testing and to manufacturing.
Excellgene offers CHO Cell Line Development, HEK Cell Line Development, and cGMP Cell Bank Manufacturing.
Excellgene has 1 investor. Key investors include ARCHIMED.
Excellgene operates through Excellgene Sa.
Yes. Excellgene was acquired by ARCHIMED in October 2025.